Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y(12) Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study.

Mathew RO, Sidhu MS, Rihal CS, Lennon R, El-Hajjar M, Yager N, Lyubarova R, Abdul-Nour K, Weitz S, O'Cochlain DF, Murthy V, Levisay J, Marzo K, Graham J, Dzavik V, So D, Goodman S, Rosenberg YD, Pereira N, Farkouh ME

Open source

DOI: 10.1007/s10557-022-07392-2
Published: 2024 Jun
Container: Cardiovascular drugs and therapy
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s10557-022-07392-2,
  title = {Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y(12) Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study.},
  author = {Mathew RO and Sidhu MS and Rihal CS and Lennon R and El-Hajjar M and Yager N and Lyubarova R and Abdul-Nour K and Weitz S and O'Cochlain DF and Murthy V and Levisay J and Marzo K and Graham J and Dzavik V and So D and Goodman S and Rosenberg YD and Pereira N and Farkouh ME},
  year = {2024},
  journal = {Cardiovascular drugs and therapy},
  doi = {10.1007/s10557-022-07392-2},
  url = {https://doi.org/10.1007/s10557-022-07392-2}
}

RIS

TY  - JOUR
TI  - Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y(12) Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study.
AU  - Mathew RO
AU  - Sidhu MS
AU  - Rihal CS
AU  - Lennon R
AU  - El-Hajjar M
AU  - Yager N
AU  - Lyubarova R
AU  - Abdul-Nour K
AU  - Weitz S
AU  - O'Cochlain DF
AU  - Murthy V
AU  - Levisay J
AU  - Marzo K
AU  - Graham J
AU  - Dzavik V
AU  - So D
AU  - Goodman S
AU  - Rosenberg YD
AU  - Pereira N
AU  - Farkouh ME
PY  - 2024
JO  - Cardiovascular drugs and therapy
DO  - 10.1007/s10557-022-07392-2
UR  - https://doi.org/10.1007/s10557-022-07392-2
ER  -

APA

RO, M., MS, S., CS, R., R, L., M, E., N, Y., R, L., K, A., S, W., DF, O., V, M., J, L., K, M., J, G., V, D., D, S., S, G., YD, R., N, P., & ME, F. (2024). Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y(12) Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study.. Cardiovascular drugs and therapy. https://doi.org/10.1007/s10557-022-07392-2

Source records

pubmed · retrieved 2026-09-27T07:00:02.795Z